Quince Therapeutics, Inc. (IRLA): Shareholders' Equity
-$35.71M
As of 2025-12-31
-$35.32M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$35.71M | n/m | 2026-04-10, Balance as of period end |
| 2024-12-31 | $30.15M | -64.6% | 2026-04-10, Balance as of period end |
| 2023-12-31 | $85.08M | -15.4% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $100.59M | -15.2% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $118.59M | -31.2% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $172.26M | +49.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $115.48M | n/m | 2022-03-01, Balance as of period end |
| 2018-12-31 | -$32.63M | n/a | 2021-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | -$35.71M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $67.48M | -3.6% |
| LeonaBio, Inc. (LONA) | 2025-12-31 | $27.79M | -38.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$187.76M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $53.55M | n/m |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $94.87M | -21.1% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $48.23M | +11.6% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $62.53M | +59.9% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
Compare IRLA, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗